Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial [PDF]
Lancet, The, 2020 BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia.
Jerome Robert +2 more
exaly +5 more sources
Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru [PDF]
, 2016 Background : Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance ...
Gotuzzo, Eduardo +6 more
core +21 more sources
Antibiotics, 2023 Background. Rifampicin is a pillar in the treatment of periprosthetic joint infection (PJI). However, rifampicin resistance is an increasing threat to PJI treatment.
Stergios Lazarinis +3 more
doaj +1 more source
Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort study. [PDF]
PLoS ONE, 2015 INTRODUCTION:Rifampicin has been used as adjunctive therapy in Staphylococcus aureus bacteraemia (SAB) with a deep infection focus. However, data for prognostic impact of rifampicin therapy is unestablished including the optimal initiation time point. We
Erik Forsblom +2 more
doaj +1 more source
Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor γ in Mouse Liver. [PDF]
PLoS ONE, 2016 Previous study found that rifampicin caused intrahepatic cholestasis. This study investigated the effects of rifampicin on hepatic lipid metabolism. Mice were orally administered with rifampicin (200 mg/kg) daily for different periods.
Jia-Hui Huang +5 more
doaj +1 more source
Journal of Infection in Developing Countries, 2021 Approximately 1.41 million people die annually due to tuberculosis. One of the main problems in Tuberculosis eradication is the development of resistance to various antibiotics.
Muhammad Habiburrahman +2 more
doaj +1 more source
İstanbul Tıp Fakültesi Dergisi, 2022 Objective: The aim of this study was to evaluate the GenoType®MTBDRplus test for detection of rifampicin (RIF) resistance in MDR Mycobacterium tuberculosis complex strains.
Esra Yıldırım Servi, Meltem Uzun
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2020 Objectives: Study of the rifampicin resistance of Rhodococcus equi strains isolated from French horses over a 20-year period. Methods: Rifampicin susceptibility was tested by disk diffusion (DD) and broth macrodilution methods, and rpoB gene sequencing ...
Sandrine Petry +10 more
doaj +1 more source
Туберкулез и болезни лёгких, 2023 The objective: to evalute effectiveness in clinical trials of the new kit of reagents of AmpliTest® MBT-Resist-I based on real-time PCR (RT-PCR) versus similar kits of reagent registered in Russia, to identify genetic markers of M.
Yu. L. Mikulovich +5 more
doaj +1 more source
Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]
, 2016 Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard +13 more
core +10 more sources